Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Tackle Critical Generics Issue In Switch Paradigm Debate

This article was originally published in The Tan Sheet

Executive Summary

Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.

Advertisement

Related Content

FDA OTC Switch Guidance Omits Some Turns As Approval Roadmap, CHPA Says
FDA OTC Switch Guidance Omits Some Turns As Approval Roadmap, CHPA Says
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Combo Products Guidance Could Help Point Novel OTC Switches In Right Direction
Combo Products Guidance Could Help Point Novel OTC Switches In Right Direction
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
Pharmacists See Challenges, Opportunities In Behind-The-Counter Class

Topics

Advertisement
UsernamePublicRestriction

Register

PS105614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel